Literature DB >> 16814262

Chronic nicotine doses down-regulate PDE4 isoforms that are targets of antidepressants in adolescent female rats.

Oksana O Polesskaya1, Robert F Smith, Karl J Fryxell.   

Abstract

BACKGROUND: Previous data in humans and animal models has suggested connections between anxiety, depression, smoking behavior, and nicotine dependence. The importance of these connections has been confirmed by clinical studies that led to the recent FDA approval of an anti-depressant (Zyban) for use in human smoking cessation programs. Other anti-depressants (such as rolipram) specifically inhibit PDE4 phosphodiesterases.
METHODS: We used DNA microarrays to discover gene expression changes in adolescent female rats following chronic nicotine treatments, and real-time PCR assays to confirm and extend those results.
RESULTS: We found a consistent decrease in the mRNA levels encoded by the Pde4b gene in nucleus accumbens, prefrontal cortex, and hippocampus of adolescent female rats treated with .24 mg/day nicotine, and in prefrontal cortex of adolescent female rats treated with .12 mg/day nicotine. We further show that each of these brain areas produced a different profile of Pde4b isoforms.
CONCLUSIONS: Chronic nicotine treatments produce a dose-dependent down-regulation of Pde4b, which may have an antidepressant effect. This is the first report of a link between nicotine dependence and phosphodiesterase gene expression. Our results also add to the complex interrelationships between smoking and schizophrenia, because mutations in the PDE4B gene are associated with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814262     DOI: 10.1016/j.biopsych.2006.03.038

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Chronic Nicotine Alters Corticostriatal Plasticity in the Striatopallidal Pathway Mediated By NR2B-Containing Silent Synapses.

Authors:  Jianxun Xia; Allison M Meyers; Jeff A Beeler
Journal:  Neuropsychopharmacology       Date:  2017-05-02       Impact factor: 7.853

2.  Nicotine preference and affective behavior of Cd81 knockout mice.

Authors:  R Logan Murphy; Laura L Locklear; M Haris Niaz; Rebecca L Walton; Alexandra D Hudson; Karl J Fryxell
Journal:  Psychopharmacology (Berl)       Date:  2021-09-07       Impact factor: 4.530

3.  Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).

Authors:  Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2007-08-15       Impact factor: 7.853

4.  Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.

Authors:  Yun-Feng Li; Ying Huang; Simon L Amsdell; Lan Xiao; James M O'Donnell; Han-Ting Zhang
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

5.  Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels.

Authors:  Hannah Murdoch; Shaun Mackie; Daniel M Collins; Elaine V Hill; Graeme B Bolger; Enno Klussmann; David J Porteous; J Kirsty Millar; Miles D Houslay
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

6.  Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use.

Authors:  Mengzhen Liu; Yu Jiang; Robbee Wedow; Yue Li; David M Brazel; Fang Chen; Gargi Datta; Jose Davila-Velderrain; Daniel McGuire; Chao Tian; Xiaowei Zhan; Hélène Choquet; Anna R Docherty; Jessica D Faul; Johanna R Foerster; Lars G Fritsche; Maiken Elvestad Gabrielsen; Scott D Gordon; Jeffrey Haessler; Jouke-Jan Hottenga; Hongyan Huang; Seon-Kyeong Jang; Philip R Jansen; Yueh Ling; Reedik Mägi; Nana Matoba; George McMahon; Antonella Mulas; Valeria Orrù; Teemu Palviainen; Anita Pandit; Gunnar W Reginsson; Anne Heidi Skogholt; Jennifer A Smith; Amy E Taylor; Constance Turman; Gonneke Willemsen; Hannah Young; Kendra A Young; Gregory J M Zajac; Wei Zhao; Wei Zhou; Gyda Bjornsdottir; Jason D Boardman; Michael Boehnke; Dorret I Boomsma; Chu Chen; Francesco Cucca; Gareth E Davies; Charles B Eaton; Marissa A Ehringer; Tõnu Esko; Edoardo Fiorillo; Nathan A Gillespie; Daniel F Gudbjartsson; Toomas Haller; Kathleen Mullan Harris; Andrew C Heath; John K Hewitt; Ian B Hickie; John E Hokanson; Christian J Hopfer; David J Hunter; William G Iacono; Eric O Johnson; Yoichiro Kamatani; Sharon L R Kardia; Matthew C Keller; Manolis Kellis; Charles Kooperberg; Peter Kraft; Kenneth S Krauter; Markku Laakso; Penelope A Lind; Anu Loukola; Sharon M Lutz; Pamela A F Madden; Nicholas G Martin; Matt McGue; Matthew B McQueen; Sarah E Medland; Andres Metspalu; Karen L Mohlke; Jonas B Nielsen; Yukinori Okada; Ulrike Peters; Tinca J C Polderman; Danielle Posthuma; Alexander P Reiner; John P Rice; Eric Rimm; Richard J Rose; Valgerdur Runarsdottir; Michael C Stallings; Alena Stančáková; Hreinn Stefansson; Khanh K Thai; Hilary A Tindle; Thorarinn Tyrfingsson; Tamara L Wall; David R Weir; Constance Weisner; John B Whitfield; Bendik Slagsvold Winsvold; Jie Yin; Luisa Zuccolo; Laura J Bierut; Kristian Hveem; James J Lee; Marcus R Munafò; Nancy L Saccone; Cristen J Willer; Marilyn C Cornelis; Sean P David; David A Hinds; Eric Jorgenson; Jaakko Kaprio; Jerry A Stitzel; Kari Stefansson; Thorgeir E Thorgeirsson; Gonçalo Abecasis; Dajiang J Liu; Scott Vrieze
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.